Deals In Depth, January 2025

Ten $1bn+ alliances were penned in January, and two exceeded $2bn.

Deals In Depth

In the top alliance by deal value, Orna Therapeutics (through its ReNAgade Therapeutics subsidiary) entered a three-year research collaboration with Vertex Pharmaceuticals designed to use Orna’s novel lipid nanoparticle delivery vehicles to improve Vertex’s efforts in developing next-generation, gene editing therapies for patients with sickle cell disease and transfusion-dependent Beta thalassemia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

More from Market Intelligence

Reforming The Rx Rulers: A New Script For PBMs

 
• By 

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis Asset

 
• By 

Nicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.

BioBytes: AI-Related Deals In Q1 2025

 
• By 

AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.